Th2 cytokines and asthma — The role of interleukin-5 in allergic eosinophilic disease

Respiratory Research

Robert W Egan¹  Richard W Chapman¹  Francis M Cuss¹  Shelby P Umland¹  Scott Greenfeder¹ 

[1] Allergy Department, Schering Plough Research Institute, Kenilworth, New Jersey, USA

关键词: interleukin-5;    eosinophil;    asthma;    allergy;   

Others  :  1227458
DOI  :  10.1186/rr41

 received in 2000-12-22, accepted in 2001-02-19,  发布年份 2001

【 摘 要 】

Interleukin-5 is produced by a number of cell types, and is responsible for the maturation and release of eosinophils in the bone marrow. In humans, interleukin-5 is a very selective cytokine as a result of the restricted expression of the interleukin-5 receptor on eosinophils and basophils. Eosinophils are a prominent feature in the pulmonary inflammation that is associated with allergic airway diseases, suggesting that inhibition of interleukin-5 is a viable treatment. The present review addresses the data that relate interleukin-5 to pulmonary inflammation and function in animal models, and the use of neutralizing anti-interleukin-5 monoclonal antibodies for the treatment of asthma in humans.

【 授权许可】

   
2001 BioMed Central Ltd

【 参考文献 】

• [1]Kay AB: Asthma and inflammation. J Allergy Clin Immunol 1991, 87:893-910.
• [2]Gleich GJ, Kita H, Adolphson CR: Eosinophils. In: Samters Immunologic Diseases, edn 5. Edited by Frank MN, Austen KF, Cloman HN, Inanue ER. Boston: Little Brown Co.; 1995, 205-245.
• [3]Clutterbuck E, Shields JG, Gorden J, Smith SH, Boyd A, Callard RE, Campbell HD, Young IG, Sanderson CJ: Recombinant human interleukin-5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol 1987, 17:1743-1750.
• [4]Clutterbuck EJ, Hirst EMA, Sanderson CJ: Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6 and GM-CSF. Blood 1989, 73:1504-1512.
• [5]Clutterbuck EJ, Sanderson CJ: Regulation of human eosinophil precursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6 and rh granulocyte-macrophage colony stimulating factor. Blood 1990, 75:1774-1779.
• [6]Mckenzie ANJ, Ely B, Sanderson CJ: Mutated interleukin-5 monomers are biologically inactive. Mol lmmunol 1991, 28:155-158.
• [7]Hirai K, Yamaguchi M, Misaki Y, Takaishi T, Ohfa K, Morita Y, Ito K, Miyamoto T: Enhancement of human basophil histamine release by interleukin 5. J Exp Med 1990, 172:1525-1528.
• [8]Resnick MB, Weller PF: Mechanisms of eosinophil recruitment. Am J Respir Cell Mol Biol 1993, 8:349-355.
• [9]Tavernier J, Devos R, Cornelis S, Tuypens T, van der Heyden J, Fiers W, Plaetinck G: A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5 specific α chain and a β chain shared with the receptor for GM-CSF. Cell 1991, 66:1175-1184.
• [10]Miyajima A, Kitamura T, Harada N, Yokota T, Arai KI: Cytokine receptors and signal transduction. Annu Rev lmmunol 1992, 10:295-331.
• [11]Gulbenkian AR, Egan RW, Fernandez X, Jones H, Kreutner W, Kung TT, Payvandi F, Sullivan L, Zurcher JA, Watnick AS: lnterleukin-5 modulates eosinophil accumulation in allergic guinea pig lung. Am Rev Respir Dis 1992, 146:263-265.
• [12]Kung TT, Stelts D, Zurcher JA, Watnick AS, Jones H, Mauser PJ, Fernandez X, Umland S, Kreutner W, Chapman RW, Egan RW: Mechanisms of allergic pulmonary eosinophilia in the mouse. J Allergy Clin lmmunol 1994, 94:1217-1224.
• [13]Mauser PJ, Pitman A, Witt A, Fernandez X, Zurcher J, Kung TT, Jones H, Watnick AS, Egan RW, Kreutner W, Adams GK III: Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am Rev Respir Dis 1993, 148:1623-1627.
• [14]Mauser PJ, Pitman AM, Fernandez X, Foran SK, Adams GK III, Kreutner W, Egan RW, Chapman RW: Effects of an antibody to IL-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995, 152:467-472.
• [15]Demonchy JG, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, Devries K: Bronchoalveolar eosinophilia during antigen-induced late asthmatic reactions. Am Rev Respir Dis 1985, 131:373-376.
• [16]Gibson PG, Manning PJ, O'Byrne PM, Girgis-Gabardo A, Dolovich J, Denburg JA, Hargreave FE: Allergen-induced asthmatic responses. Relationship between increases in airway responsiveness and increases in circulating eosinophils, basophils and their progenitors. Am Rev Respir Dis 1991, 143:331-335.
• [17]Hutson PA, Church MK, Clay TP, Miller P, Holgate ST: Early and late-phase bronchoconstriction after antigen challenge of nonanesthetized guinea pigs. 1. The association of disordered airway physiology to leukocyte infiltration. Am Rev Respir Dis 1988, 137:548-557.
• [18]Ishida K, Thompson RJ, Beattie LL, Wiggs B, Schellenberg RR: Inhibition of antigen-induced airway hyperresponsiveness but not acute hypoxia nor airway eosinophilia, by an antagonist of platelet-activating factor. J Immunol 1990, 144:3907-3911.
• [19]Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG: Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996, 183:195-201.
• [20]Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, Ovington KS, Behm CA, Kohler G, Young IG, Matthaei KI: IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996, 4:15-24.
• [21]Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley H, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000, 356:2144-2148.
• [22]Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HAM, Postma DS, Danzig M, Cuss F, Pauwels RA: Results of a phase I trial with SCH5 a humanized anti-IL-5 antibody, in severe persistent asthma [abstract]. Am J Respir Crit Care Med 2000, 161:A505.
• [23]van Leeuwen BH, Martinson ME, Webb GC, Young IG: Molecular organization of the cytokine gene cluster, involving, the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. Blood 1989, 73:1142-1148.
• [24]Azuma C, Tanabe T, Konishi M, Kinashi T, Noma T, Matsuda F, Yaoita Y, Takatsu K, Hammarstrom L, Edvard-Smith Cl, Severinson E, Honio T: Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue. Nucl Acids Res 1986, 14:9149-9158.
• [25]Kinashi T, Harada N, Severinson E, Tanabe T, Sideras P, Konishi M, Azuma C, Tomiaga A, Bergstedt-Lindqvist S, Takahashi M, Matsuda F, Yaoita Y, Takatsu K, Honjo T: Cloning of complementary DNA encoding T-cell replacing factor and identity with B-cell growth factor II. Nature 1986, 324:70-73.
• [26]Miyatake S, Shlomai J, Ken-Ichi A, Ari N: Characterization of the mouse granulocyte macrophage colony-stimulating factor (GM-CSF) gene promoter: nuclear factors that interact with an element shared by three lymphokine genes - those for GM-CSF, interleukin-4 (IL-4), and IL-5. Mol Cell Biol 1991, 12:5894-5901.
• [27]Minamitake Y, Kodama S, Katayama T, Adachi H, Tanaka H, Tsujimoto M: Structure of recombinant human interleukin 5 produced by chinese hamster ovary cell. J Biochem 1990, 107:292-297.
• [28]Takahashi T, Yamaguchi N, Mita S, Yamaguchi Y, Suda T, Tominaga A, Kikuchi Y, Miura Y, Takatsu K: Structural comparison of murine T-cell (Bl 51 Kl 2) derived T-cell-replacing factor (IL-5) with rIL-5: dimer formation is essential for the expression of biological activity. Mol lmmunol 1990, 27:911-920.
• [29]Dickason RR, Huston MM, Huston DP: Delineation of IL-5 domains predicted to engage the IL-5 receptor complex. J Immunol 1996, 156:1030-1037.
• [30]Zhang J, Kuvelkar R, Murgolo NJ, Taremi SS, Chou CC, Wang P, Billah MM, Egan RW: Mapping and characterization of the epitope(s) of Sch 5 a humanized mAb, that inhibits human IL-5. Int Immunol 1999, 11:1935-1944.
• [31]Kodama S, Tsuruoka N, Tsujimoto M: Role of the C-terminus in the biological activity of human interleukin 5. Biochem Biophys Res Commun 1991, 178:514-519.
• [32]Tominaga A, Takahashi T, Kikuchi Y, Mita S, Naomi S, Harada N, Yamaguchi N, Takatsu K: Role of carbohydrate moiety of IL-5. J Immunol 1990, 144:1345-1352.
• [33]Milburn MV, Hassell AM, Lambert MH, Jordan SR, Proudfoot AEI, Graber P, Wells TNC: A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5. Nature 1993, 363:172-176.
• [34]Mosmann TR, Coffman RL: TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann Rev lmmunol 1989, 7:145-173.
• [35]Altman A, Coggeshall KM, Mustelin T: Molecular events mediating T cell activation. Adv Immunol 1990, 48:227-360.
• [36]Naora H, Altin JG, Young IG: TCR-dependent and independent signaling mechanisms differentially regulate lymphokine gene expression in the murine T helper clone DlO.G4.1. J lmmunol 1994, 152:5691-5702.
• [37]van Straaten JFM, Dokter WHA, Stulp BK, Vellenga BK: The regulation of interleukin-5 and interleukin-3 gene expression in human T cells. Cytokine 1994, 6:229-234.
• [38]Garlisi CG, Falcone A, Kung TT, Stelts D, Pennline KG, Beavis AJ, Smith SR, Egan RW, Umland SP: T cells are necessary for TH2 cytokine production and eosinophil accumulation in airways of antigen-challenged allergic mice. Clin lmmunol lmmunopathol 1995, 75:75-83.
• [39]Umland SP, Razac S, Shah H, Nehrebne DK, Egan RW, Billah MM: Interleukin-5 mRNA stability in human T cells is regulated differently than interleukin-2, interleukin-3, interleukin-4, granulocyte/macrophage colony-stimulating factor, and interferon-γ. Am J Respir Cell Mol Biol 1998, 18:631-642.
• [40]Umland SP, Shah H, Jakway JP, Shortall J, Razac S, Garlisi CF, Falcone A, Kung TT, Stelts D, Hegde V, Patel M, Billah MM, Egan RW: Effects of cyclosporin A and dinactin on T-cell proliferation, interleukin-5 production, and murine pulmonary inflammation. Am J Respir Cell Mol Biol 1999, 20:481-492.
• [41]Bradding P, Roberts JA, Britten KM, Montefort S, Dujukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST: Interleukin-4, -5, and -6 and tumor necrosis factor-α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994, 10:471-480.
• [42]Dubucquoi S, Desreumaux P, Janin A, Klein O, Goldman M, Tavernier J, Capron A, Capron M: Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994, 179:703-708.
• [43]Bazan JF: Structural design and molecular evaluation of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990, 87:6934-6938.
• [44]Migita M, Yamaguchi N, Mita S, Higuchi S, Hitoshi Y, Yosha Y, Tomonaga M, Matsuda I, Tominaga A, Takatsu K: Characterization of the human IL-5 receptors on eosinophils. Cell lmmunol 1991, 133:484-497.
• [45]Plaetinck G, van der Heyden J, Tavernier J, Fache I, Tuypens T, Fischkoff S, Fiers W, Devos R: Characterization of interleukin 5 receptors on eosinophilic sublines from human promyelocytic leukemia (HL-60) cells. J Exp Med 1990, 172:683-691.
• [46]Murata Y, Takaki S, Migita M, Kikuchi Y, Tominaga A, Takatsu K: Molecular cloning and expression of the human interleukin 5 receptor. J Exp Med 1992, 175:341-351.
• [47]Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Thierfelder WE, Kreider B, Silvennoinen O: Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994, 19:222-227.
• [48]Darnell JE Jr, Kerr AM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 262:1415-1420.
• [49]Mul Al-F, Wakao H, O'Farrell A-M, Harada N, Miyajima A: lnterleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologues. EMBO J 1995, 14:1166-1175.
• [50]Lopez AF, Shannon MF, Chia M-M, Park L, Vadas MA: Regulation of human eosinophil production and function by interleukin-5. lmmunol Ser 1992, 57:549-571.
• [51]Yamaguchi Y, Suda T, Suda J, Eguchi M, Miura Y, Harad N, Taminaga A, Takatsu K: Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988, 167:43-56.
• [52]Warringa RAJ, Schweizer RC, Maikoe T, Kujiper PHM, Bruijnzeel PLB, Koenderman L: Modulation of eosinophil chemotaxis by interleukin-5. Am J Respir Cell Mol Biol 1992, 7:631-636.
• [53]Carlson M, Peterson C, Venge P: The infuence of IL-3, IL-5 and GM-CSF on normal human eosinophil and neutrophil C3b-induced degranulation. Allergy 1993, 48:437-442.
• [54]Kita H, Weiler D, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ: Release of granule proteins from eosinophils cultured with IL-5. J lmmunol 1992, 149:629-635.
• [55]Yamaguchi Y, Suda T, Oha S, Toinaga K, Miura Y, Kasahara T: Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 1991, 78:2542-2547.
• [56]Woolley MJ, Denburg JA, Ellis R, Dahlback M, O'Byrne P: Allergen-induced changes in bone marrow progenitors and airway responsiveness in dogs and the effect of inhaled budesonide on these parameters. Am J Respir Cell Mol Biol 1994, 11:600-606.
• [57]Ohnishi T, Sur S, Collins DS, Fish J, Gleich GJ, Peters SP: Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J Allergy Clin Immunol 1993, 92:607-615.
• [58]Wallen N, Kita H, Weiler D, Gleich GJ: Glucocorticoids inhibit cytokine-mediated eosinophil survival. J lmmunol 1991, 147:3490-3495.
• [59]Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ: IgA-induced eosinophil degranulation. J Immunol 1989, 142:2393-2400.
• [60]Minnicozzi M, Anthes JC, Siegel Ml, Billah MM, Egan RW: Activation of phospholipase D in normodense human eosinophils. Biochem Biophys Res Commun 1990, 170:540-547.
• [61]Petreccia DC, Nauseef WM, Clark RA: Respiratory burst of normal human eosinophils. J Leuk Biol 1987, 41:283-288.
• [62]Yazdanbakhsh M, Eckmann CM, Koenderman L, Verhoeven AJ, Roos D: Eosinophils do respond to FMLP. Blood 1987, 70:379-383.
• [63]Bruynzeel PLB, Kok PTM, Hamelink ML, Kijne AM, Verhagen J: Exclusive leukotrine C4 synthesis by purified human eosinophils induced by opsonized zymosan. FEBS Lett 1985, 189:350-354.
• [64]Cockcroft S: G-protein-regulated phospholipase C, D, and A2-mediated signalling in neutrophils. Biochim Biophys Acta 1992, 1113:135-160.
• [65]Lehrer RI, Ganz T, Selsted ME, Babior BM, Curnutte JT: Neutrophils and host defense. Ann Intern Med 1988, 109:127-142.
• [66]Gleich GJ, Adolphson CR: The eosinophilic leukocyte: structure and function. Adv lmmunol 1986, 39:177-253.
• [67]Hamann KJ, Barker RI, Ten RM, Gleich GJ: The molecular biology of eosinophil granule proteins. Int Arch Allergy Appl lmmunol 1991, 94:202-209.
• [68]Minnicozzi M, Duran WN, Gleich GJ, Egan RW: Eosinophil granule proteins increase microvascular macromolecular transport in the hamster cheek pouch. J Immunol 1994, 153:2664-2670.
• [69]Frigas E, Loegering DA, Gleich GJ: Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. J Lab Invest 1980, 42:35-43.
• [70]Coeffier E, Joseph D, Vargaftig BB: Role of interleukin-5 in enhanced migration of eosinophils from airways of immunized guinea pigs. Br J Pharmacol 1994, 113:749-756.
• [71]Lilly CM, Chapman RW, Sehring SJ, Mauser PJ, Showell HJ, Egan RW, Drazen JM: Effects of interleukin 5-induced pulmonary eosinophilia on airway reactivity in the guinea pig. Am J Physiol 1996, 270:L368-L375.
• [72]Hakonarson H, Maskeri N, Carter C, Chuang S, Grunstein MM: Autocrine interaction between IL-5 and IL-1β mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle. J Clin Invest 1999, 104:657-667.
• [73]Elbon CL, Jacoby DB, Fryer AD: Pretreatment with an antibody to interleukin 5 prevents loss of pulmonary M2 muscarinic receptor function in antigen challenged guinea pigs. Am J Respir Cell Mol Biol 1995, 12:320-328.
• [74]Kung TT, Jones H, Adams GK III, Umland SP, Kreutner W, Egan RW, Chapman RW, Watnick AS: Characterization of a murine model of allergic pulmonary inflammation. Int Arch Allergy Immunol 1994, 105:83-90.
• [75]Kung TT, Stelts DM, Zurcher JA, Adams GK III, Egan RW, Kreutner W, Watnick AS, Jones H, Chapman RW: Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995, 13:360-365.
• [76]Kung TT, Stelts D, Zurcher JA, Jones H, Umland SP, Kreutner W, Egan RW, Chapman RW: Mast cells modulate allergic pulmonary eosinophilia in mice. Am J Respir Cell Biol 1995, 12:404-409.
• [77]Brusselle GG, Kips JC, Tavernier JH, van der Heyden JG, Cavelier CA, Pauwels RA, Bluethmann H: Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 1994, 24:73-80.
• [78]Webb DC, McKenzie ANJ, Koskinen AML, Yang M, Mattes J, Foster PS: Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 2000, 165:108-113.
• [79]Mould AW, Ramsay AJ, Matthaei KI, Young IG, Rothenberg ME, Foster PS: The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity. J Immunol 2000, 164:2142-2150.
• [80]Gundel RH, Wegner CD, Letts LG: Antigen-induced acute and late-phase responses in primates. Am Rev Respir Dis 1992, 146:369-373.
• [81]Adelroth E, Rosenhall L, Johansson S, Linden M, Venge P: Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. Am Rev Respir Dis 1990, 142:91-99.
• [82]Broide DH, Pain MM, Firestein GS: Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992, 90:1414-1424.
• [83]Fukuda T, Nakajima H, Fukushima Y, Akutsu I, Namao T, Majima K, Motojima S, Sato Y, Takatsu K, Makino S: Detection of interleukin-5 messenger RNA and interleukin-5 protein in bronchial biopsies from asthma by nonradioactive in situ hybridization and immunohistochemistry. J Allergy Clin lmmunol 1994, 94:584-593.
• [84]Hamid Q, Azzawi M, Ying S, Moqbel R, Wardlaw AJ, Corrigan CJ, Bradley B, Durham SR, Collins JV, Jeffery PK, Quint DJ, Kay AB: Interleukin-5 mRNA in mucosal bronchial biopsies from asthmatic subjects. Int Arch Allergy Appl lmmunol 1991, 94:169-170.
• [85]Krishnaswamy G, Liu MC, Su S-N, Kumai M, Ziao H-Q, Marsh DG, Huang SK: Analysis of cytokine transcripts in the bronchoalveolar lavage cells of patients with asthma. Am J Respir Cell Mol Biol 1993, 9:279-286.
• [86]Robinson DS, Ying S, Bentley AM, Meng Q, North J, Durham SR, Kay AB, Hamid Q: Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in asthma. J Allergy Clin Immunol 1993, 92:397-403.
• [87]Robinson DS, Hamid Q, Ting S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992, 326:298-304.
• [88]Bentley AM, Qiu Meng DS, Robinson DS, Hamid Q, Kay AB, Durham SR: Increases in activated T lymphocytes, eosinophils and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993, 8:35-42.
• [89]Walker C, Bauer W, Braun RK, Menz G, Braun P, Schwarz F, Hansel T-F, Villiger B: Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med 1994, 150:1030-1048.
• [90]Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB: Phenotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon γ cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995, 12:477-487.
• [91]Hamid Q, Boguniewicz M, Leung DYM: Differential in situ cytokine gene expession in acute versus chronic atopic dermatitis. J Clin Invest 1994, 94:870-876.
• [92]Kay AB, Ying S, Varney J, Gaga M, Durham SR, Moqbel R, Wardlaw AJ, Hamid Q: Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 1991, 173:775-778.
• [93]Tanaka Y, Delaporte E, Dubucquoi S, Gounni AS, Porchet E, Capron A, Capron M: lnterleukin-5 messenger RNA and immunoreactive protein expression by activated eosinophils in lesional atopic dermatitis skin. J Invest Dermatol 1994, 103:589-592.
• [94]Bradding P, Feather IH, Wilson S, Bardin PG, Heusser CH, Holgate ST, Howarth PH: Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. J Immunol 1993, 151:3853-3865.
• [95]Ying S, Durham SR, Barkans J, Masuyama K, Jacobson M, Rak S, Lowhagen O, Moqbel R, Kay AB, Hamid QA: T cells are the principal source of interleukin 5 mRNA in allergen-induced rhinitis. Am J Respir Cell Mol Biol 1993, 9:356-360.
• [96]Durham SR, Kay AB: Eosinophils, bronchial hyperreactivity and late phase asthmatic reactions. Clin Allergy 1985, 13:411-418.
• [97]Wardlaw AJ, Dunnett S, Gleich GJ, Collins JV, Kay AB: Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988, 137:62-69.
• [98]Ohnishi T, Kita H, Weiler D, Sur S, Sedgwick JB, Calhoun WJ, Busse WW, Abrams JS, Gleich GJ: IL-5 is the predominant eosinophil-active cytokine in the antigen induced pulmonary late-phase reaction. Am Rev Respir Dis 1993, 147:901-907.
• [99]Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR: Activation of CD4+ T cells, increased Th2-type cytokine mRNA expression and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Imunol 1993, 92:313-324.
• [100]Sedgwick JB, Calhoun WC, Gleich GJ, Kita H, Abrams JS, Schwartz LB, Volovitz B, Ben-Yaakov M, Busse WW: Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis 1991, 144:1274-1281.
• [101]Terada N, Konno A, Natori T, Tada H, Togawa K: lnterleukin-5 preferentially recruits eosinophils from vessels in nasal mucosa. Acta Otolaryngol Suppl 1993, 506:57-60.
• [102]Terada N, Konno A, Tada H, Shirotori K, Ishikawa K, Togawa K: The effect of recombinant human interleukin-5 on eosinophil accumulation and degranulation in human nasal mucosa. J Allergy Clin Immunol 1992, 90:160-168.
• [103]Corrigan CJ, Haczku A, Gemou-Engesaeth V, Dol S, Kukuchi Y, Takatsu K, Durham SR, Kay AB: CD4 T-Lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Am Rev Respir Dis 1993, 147:540-547.
• [104]Motojima S, Akutsu I, Fukuda T, Makino S, Takatsu K: Clinical significance of measuring levels of sputum and serum ECP and serum IL-5 in bronchial asthma. Allergy 1993, 48:98-106.
• [105]Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow J-C: Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis 1992, 146:109-115.
• [106]Zangrilli JG, Shaver JR, Cirelli RA, Cho SK, Garlisi CG, Falcone A, Cuss FM, Fish JE, Peters SP: sVCAM-1 levels after segmental antigen challenge correlate with eosinophil influx, IL-4 and IL-5 production, and the late phase response. Am J Respir Crit Care Med 1995, 151:1346-1353.
• [107]Rolfe FG, Hughes JM, Armour CL, Sewell WA: Inhibition of interleukin-5 gene expression by dexamethasone. lmmunol 1992, 77:494-499.
• [108]Egan RW, Athwal E, Bodmer MW, Carter JM, Chapman RW, Chou C-C, Cox MA, Emtage JS, Fernandez X, Genatt N, Indelicato SR, Jenh C-H, Kreutner W, Kung TT, Mauser PJ, Minnicozzi M, Murgolo NJ, Narula SK, Petro ME, Schilling A, Sehring S, Stelts D, Stephens S, Taremi SS, Weiner SH, Zavodny PJ, Zurcher J: Effect of SCH 5 a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittel-Forschung 1999, 49:779-790.
• [109]Hart TK, Cook RM, Herzyk DJ, Zia-Amirhosseini P, Williams DM, Bugelski PJ: Inhibition of eosinophilia in monkeys with SB-24 a humanized anti-human IL-5 monoclonal antibody [abstract]. Am J Respir Crit Care Med 1998, 157:A744.
• [110]Zia-Amirhosseini P, Minthorn E, Benincosa LJ, Hart TK, Hottenstein CS, Tobia LAP, Davis CB: Pharmacokinetics and pharmacodynamics of SB-24 a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 1999, 291:1060-1067.